Amiodarone concentration in human myocardium after rapid intravenous administration

Cardiovascular Drugs and Therapy

Volumn 13, Issue 3, 1999, Pages 265-270

  Anastasiou Nana, Maria I ^a,b   Nanas, John N ^a   Alexopoulos, George ^a   Karli, Joanna N ^a   Margari, Zafiria J ^a   Agapitos, Emmanouel ^a   Patsi, Efrosini N ^a   Stamatelopoulos, Stamatios F ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Amiodarone; Drug hemodynamic effects; Drug myocardial concentration

Indexed keywords

AMIODARONE; ANGORON; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

ADULT; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; BODY WEIGHT; CARDIOMYOPATHY, DILATED; FEMALE; FIBROSIS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIUM; VASODILATOR AGENTS;

EID: 0033031626     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007756411790     Document Type: Article

References (43)

1. 1. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997;350:1417-1424.
2. 2. Pinto JV, Jr. Ramani K, Neelagaru S, Known M, Gheorghiade M. Amiodarone therapy in chronic heart failure and myocardial infarction: A review of the mortality trials with special attention to STAT-CHF and the GESICA trials. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. Prog Cardiovasc Dis 1997;40:85-93.
3. 3. Lee KL, Tai YT. Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: Efficacy and safety. Clin Cardiol 1997;20: 372-377.
4. 4. Kowey PR, Marinchak RA, Rials SJ, Filart RA. Intravenous amiodarone. J Am Coll Cardiol 1997;29:1190-1198.
5. 5. Nalos PC, Ismail Y, Pappas JM, Nyitray W, DonMichael TA. Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation. Am Heart J 1991;122:1629-1632.
6. 6. Ochi RP, Goldenberg IF, Almquist A, et al. Intravenous amiodarone for the rapid treatment of life-threatening ventricular arrhythmias in critically ill patients with coronary artery disease. Am J Cardiol 1989;64:599-603.
7. 7. Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995;92:3264-3272.
8. 8. Mooss AN, Mohiuddin SM, Hee TT, et al. Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia. Am J Cardiol 1990;65: 609-614.
9. 9. Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW. Amiodarone: Clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation 1983;68:88-94.
10. 10. Anastasiou-Nana MI, Anderson JL, Nanas JN, et al. High incidence of clinical and subclinical toxicity associated with amiodarone treatment of refractory tachyarrhythmias. Can J Cardiol 1986;2:138-145.
11. 11. Mason JW. Prediction of amiodarone-induced pulmonary toxicity. Am J Med 1989;86:2-3.
12. 12. Anastasiou-Nana MI, Levis GM, Moulopoulos SD. Pharmacokinetics of amiodarone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 1982;20: 524-529.
13. 13. Anastasiou-Nana MI, Levis GM, Moulopoulos SD. Amiodarone: Application and clinical pharmacology in atrial fibrillation and other arrhythmias. Int J Clin Pharmacol Ther Toxicol 1984;22:229-235.
14. 14. Levis GM, Anastasiou-Nana M, Moulopoulos S. Determination of amiodarone by high pressure liquid chromatography (HPLC). In: Turner P, Padyham C, eds. World Conference on Clin Pharm Ther, London: MacMillan, 1980, Clinical Pharmacology and Therapeutics (abstr) 0852.
15. 15. Holt DW, Tucker GT, Jackson PR, Storey GCA. Amiodarone pharmacokinetics. Am Heart J 1983;106:840-847.
16. 16. Venkatesh N, Somani P, Bersohn M, Phair R, Kato R, Singh BN. Electropharmacology of amiodarone: Absence of relationship to serum, myocardial, and cardiac sarcolemmal membrane drug concentrations. Am Heart J 1986;112: 916-922.
17. 17. Kannan R, Nademanee K, Hendrickson J, Rostami HJ, Singh BN. Amiodarone kinetics after oral dosages. Clin Pharmacol Ther 1982;31:438-444.
18. 18. Anastasiou-Nana MJ, Nanas JN, Nanas SN, et al. Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: Experimental study. J Am Coll Cardiol 1994;23:253-258.
19. 19. Nanas JN, Mason JW. Pharmacokinetics and regional electrophysiologic effects of intracoronary amiodarone administration. Circulation 1995;91:451-461.
20. 20. Riva E, Gerna M, Neyroz P, Urso R, Bartosek I, Guaitani A. Pharmacokinetics of amiodarone in rats. J Cardiovasc Pharmacol 1982;4:270-275.
21. 21. Talajic M, DeRoode MR, Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: Evidence for clinically relevant activity of the metabolite. Circulation 1987;75:265-271.
22. 22. Maggioni AP, Maggi A, Volpi A, D'Aranno V, Tognoni G, Giani P. Amiodarone distribution in human tissues after sudden death during Holter recording. Am J Cardiol 1983;52: 217-218.
23. 23. Barbieri E, Conti F, Zampieri P, et al. Amiodarone and desethylamiodarone distribution in the atrium and adipose tissue of patients undergoing short and long-term treatment with amiodarone. J Am Coll Cardiol 1986;8:210-213.
24. 24. Giardina EGV, Schneider M, Barr ML. Myocardial amiodarone and desethylamiodarone concentrations in patients undergoing cardiac transplantation. J Am Coll Cardiol 1990;16:943-947.
25. 25. Nanas JN, Anastasiou-Nana MI, Margari ZJ, Karli J, Moulopoulos SD. Redistribution of amiodarone in cardiac transplant recipients treated with the drug before operation. J Heart Lung Transpl 1997;16:387-389.
26. 26. Agapitos E, Kavantzas N, Nanas J, et al. The myocardial fibrosis in patients with dilated cardiomyopathy. Gen Diagn Pathol 1995/96;141:305-311.
27. 27. Benotti J, Benotti N. Protein bound iodine, total iodine and butanol-extractable iodine by partial automation. Clin Chem 1963;9:408-415.
28. 28. Connolly SJ, Latini R, Kates RE. Pharmacodynamics of intravenous amiodarone in the dog. J Cardiovasc Pharmacol 1984;6:531-535.
29. 29. Ikeda N, Nademanee K, Kannan R, Singh BN. Electrophysiologic effects of amiodarone: Experimental and clinical observation relative to serum and tissue drug concentrations. Am Heart J 1984;108:890-898.
30. 30. Latini R, Connolly SJ, Kates RE. Myocardial disposition of amiodarone in the dog. J Pharmacol Exp Ther 1983;224: 603-608.
31. 31. Escoubet B, Jaillon P, Berger Y, et al. Amiodarone and N-desethylamiodarone concentrations in plasma, red blood cells, and myocardium after a single oral dose: Relation to hemodynamic effects in surgical patients. Am Heart J 1986; 111:280-285.
32. 32. Plomp TA, Hauer RNW, De-Medina EOR. Amiodarone and desethylamiodarone concentrations in plasma and tissues of surgical treated patients on long-term oral amiodarone treatment. In Vivo 1990;4:97-100.
33. 33. Escoubet B, Coumel P, Poirier JM, et al. Suppression of arrhythmias within hours after a single oral dose of amiodarone and relation to plasma and myocardial concentrations. Am J Cardiol 1985;55:696-702.
34. 34. Haffajee CI, Love JC, Canada AT, Lesko LJ, Asdourian G, Alpert JS. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation 1983; 67:1347-1355.
35. 35. Bandyopadhyay S, Somani P. A comparison of plasma, white blood cell, red blood cell, and tissue distribution of amiodarone and desethylamiodarone in anesthetized dogs. J Cardiovasc Pharmacol 1987;10:379-388.
36. 36. Kannan R, Ikeda N, Wagner R, et al. Serum and myocardial kinetics of amiodarone and its desethyl metabolite after intravenous administration in rabbits. J Pharm Sci 1984; 73:1208-1211.
37. 37. Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997;127:294-303.
38. 38. Debbas NMG, Du Cailar C, Bexton RS, Demaille JG, Camm AJ, Puech P. The QT interval: A predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J 1984; 51:316-320.
39. 39. Levine JH, Maasumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. J Am Coll Cardiol 1996;27:67-75.
40. 40. Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995;92:3255-3263.
41. 41. Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 1996; 27:1079-1082.
42. 42. Kerin NZ, Faitel K, Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs. quinidine for conversion of atrial fibrillation. Arch Intern Med 1996;156:49-53.
43. 43. Gallik DM, Meissner MD, Communale M, Singer I, Hanin L. Favorable hemodynamic effects of Amio-Aqueous®, a new formulation of intravenous amiodarone. Circulation 1997; 96:I383.